Submodule
The Chronic HFrEF Treatment Framework
The modern HFrEF foundation uses four complementary pillars early, with individualized sequencing and rapid follow-up rather than a rigid one-drug-at-a-time ladder.
- Four pillars
- Rapid sequencing
- Compensation
- Monitoring and access
Pressure, kidney, potassium
Start when compensated
Potassium surveillance
Diabetes not required
Build broad protection early
ARNI or another indicated RAS inhibitor, an evidence-based beta blocker, an MRA, and an SGLT2 inhibitor address distinct pathways. Low doses of all tolerated pillars generally provide broader early protection than maximizing only one or two.
Sequence by physiology
Congestion, perfusion, blood pressure, pulse, kidney function, potassium, angioedema history, diabetes and fasting risk, and access determine the safest next step. Beta-blocker initiation and escalation wait for compensation, while MRA and SGLT2 therapy often have less pressure effect.
Move with purpose
Contemporary care aims to establish and move toward maximally tolerated therapy within about three months when feasible. Hospital and transition visits are opportunities, but every start needs early laboratory and clinical follow-up.
Treat implementation as therapy
Cost, prior authorization, transportation, health literacy, cognition, adverse effects, pill burden, language, and trust determine whether a prescription becomes exposure. Pharmacists and multidisciplinary teams convert evidence into sustained use.
Quick check
Submodule
RAS, Neprilysin, and Mineralocorticoid Therapy
ARNI, ACE inhibitors, ARBs, and MRAs modify related neurohormonal biology but require distinct transition, kidney, potassium, pressure, pregnancy, and interaction safeguards.
- Sacubitril valsartan
- ACE washout
- ACE inhibitor or ARB alternative
- MRA monitoring
Respect ACE washout
Choose one pathway
Kidney and potassium
Preserve benefit safely
Use ARNI without unsafe overlap
Sacubitril valsartan combines angiotensin-receptor and neprilysin inhibition. At least 36 hours must separate an ACE inhibitor from ARNI. Prior angioedema, pregnancy, pressure, kidney function, potassium, and volume require review.
Keep ACE inhibitors and ARBs as alternatives
When ARNI is not feasible, an ACE inhibitor or ARB can preserve RAS-modifying benefit. Routine dual or triple RAS blockade adds hypotension, kidney injury, hyperkalemia, and angioedema risk without routine value.
Use MRAs as disease therapy
Spironolactone and eplerenone reduce HFrEF events in eligible patients. Baseline kidney function and potassium determine initiation, but safety depends on early repeat testing and review of supplements, salt substitutes, NSAIDs, trimethoprim, and illness.
Respond proportionally to laboratory change
Confirm unexpected values and address volume, diet, supplements, interactions, and kidney trajectory. A single mild abnormality should trigger mechanism-based risk reduction, not automatic loss of every beneficial pathway.
Quick check
Submodule
Beta Blockers and Heart-Rate Strategy
Evidence-based beta blockade follows compensation, while ivabradine and digoxin occupy narrower roles defined by rhythm, heart rate, kidney exposure, and residual symptoms.
- Evidence-based beta blockers
- Decompensation
- Ivabradine
- Digoxin
Do not titrate in shock
Agent and formulation matter
Match mechanism
Avoid additive block
Use the agents with HFrEF evidence
Carvedilol, metoprolol succinate, and bisoprolol have outcome evidence. Start after compensation and titrate against pulse, pressure, conduction, bronchospasm, fatigue, perfusion, and symptoms.
Handle decompensation by hemodynamics
Do not initiate or escalate beta blockade during shock or active low-output decompensation. Established therapy is not automatically stopped during every admission if perfusion remains adequate and no clear intolerance exists.
Reserve ivabradine for its phenotype
Ivabradine acts at the sinus-node If current. It requires sinus rhythm, qualifying ejection fraction and resting rate, symptoms despite therapy, and maximally tolerated beta blockade or a documented limit.
Use digoxin for a defined goal
Digoxin may reduce hospitalization or help rate control in selected patients but does not establish mortality benefit. Kidney function, body size, electrolytes, conduction, concentration timing, and P-gp interactions govern safety.
Quick check
Submodule
SGLT2 Therapy and Congestion Control
SGLT2 inhibitors modify heart-failure outcomes across diabetes status, while diuretics relieve volume. Safe care separates these goals and monitors fasting, illness, kidney, volume, and electrolytes.
- SGLT2 benefit
- Ketoacidosis prevention
- Loop diuretics
- Diuretic resistance
Screen fasting and illness
Measure response
Monitor sequential block
Keep the pillars
Use SGLT2 therapy beyond diabetes
Dapagliflozin and empagliflozin reduce worsening heart-failure events in eligible patients with or without diabetes. Review kidney thresholds, volume, genital infection history, insulin deficiency, acute illness, fasting, and surgery.
Teach euglycemic ketoacidosis
Nausea, vomiting, abdominal pain, dyspnea, and anion-gap acidosis require ketone evaluation even when glucose is not severely elevated. Sick-day and perioperative hold instructions belong at initiation.
Use loops to achieve euvolemia
Loop diuretics control congestion and are adjusted by weight, symptoms, jugular pressure, edema, urine response, electrolytes, kidney trajectory, adherence, sodium exposure, and NSAIDs. They do not replace the four pillars.
Diagnose resistance before stacking
Inadequate dose, poor absorption, gut edema, kidney dysfunction, low perfusion, sodium intake, NSAIDs, nephron adaptation, and a mistaken congestion assessment can all appear as resistance. Sequential blockade requires close electrolyte and volume monitoring.
Quick check
Submodule
Additional Therapy for Residual Risk
Additional medications, iron, devices, ablation, and advanced referral follow a defined phenotype and residual goal after foundational therapy is established.
- Hydralazine and nitrate
- Vericiguat
- Iron deficiency
- Device and specialty escalation
Do not skip the foundation
Use exact regimen
Know the intended benefit
Refer before decline
Use the studied vasodilator combination
Hydralazine plus isosorbide dinitrate is added for selected self-identified Black patients with advanced symptomatic HFrEF on optimal therapy and may be used when RAS therapy is not feasible in selected patients. Headache, pressure, adherence, nitrate interactions, and immune toxicity matter.
Place vericiguat after worsening
Vericiguat may be considered for selected high-risk HFrEF after recent worsening despite foundational care. It is not a substitute for the pillars. Blood pressure, anemia, pregnancy risk, and label-defined interactions require review.
Find functional iron deficiency
Ferritin and transferrin saturation identify iron deficiency with or without anemia. Inflammation can elevate ferritin, so transferrin saturation adds context. Evidence-based intravenous iron may improve symptoms and events in selected patients while the cause of deficiency is investigated.
Escalate beyond another prescription
Persistent symptoms, recurrent admissions, arrhythmia, conduction disease, valve disease, or advanced physiology can require CRT, ICD, revascularization, ablation, valve intervention, transplant, mechanical support, rehabilitation, or palliative care.
Quick check
Submodule
HFmrEF, HFpEF, HFimpEF, and Implementation
Across the ejection-fraction spectrum, current therapy combines SGLT2 benefit, decongestion, cardiometabolic and renal care, phenotype-specific options, preserved HFrEF therapy after improvement, and barrier-aware follow-up.
- HFmrEF
- HFpEF
- Obesity phenotype
- HFimpEF and implementation
SGLT2 has central evidence
Treat obesity and comorbidity
Continue disease therapy
Reassess rapidly
Treat HFmrEF as a continuum
SGLT2 inhibition has central evidence in HFmrEF. ARNI, ARB, MRA, and beta-blocker use is individualized, particularly toward the lower ejection-fraction range or after prior HFrEF. Etiology, congestion, and comorbidity still matter.
Treat HFpEF as multisystem disease
HFpEF care combines accurate diagnosis, decongestion, SGLT2 therapy, pressure control, and active management of obesity, diabetes, CKD, AF, sleep apnea, coronary disease, exercise limitation, and phenotype-specific cardiomyopathy.
Address obesity with medical seriousness
Visceral adiposity, inflammation, volume expansion, metabolic disease, sleep apnea, and reduced reserve can form a treatable HFpEF phenotype. Nutrition, exercise, incretin-based therapy when appropriate, sleep care, and social support belong beside cardiovascular treatment.
Protect improvement and solve barriers
HFimpEF is remission rather than cure, so tolerated disease-modifying therapy generally continues. Hypotension and kidney changes require trajectory-based troubleshooting. Cost, literacy, cognition, transport, adverse effects, and pill burden need targeted solutions rather than blame.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 104 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.